Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical Co., Ltd., has recently had its drug registration application for injectable lactulose red mycin accepted by the National Medical Products Administration, aimed at treating infections caused by specific microbial sensitive strains, preventing initial rheumatic fever, preventing recurrence of rheumatic fever, and preventing bacterial endocarditis [1] Group 1 - The drug registration application was accepted by the National Medical Products Administration [1] - The drug is intended for multiple therapeutic uses, including treatment of infections and prevention of rheumatic fever and bacterial endocarditis [1]

证券代码：600196 股票简称：复星医药 编号：临 2026-005 上海复星医药（集团）股份有限公司 关于参与设立之私募股权投资基金进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 单位：人民币 万元 注：系本集团出资参与方 本次转让前后，标的基金的认缴规模保持不变、本集团认缴该基金的份额比 例亦保持不变（均为 31%）。 一、参与设立之私募股权投资基金的基本情况 2023 年 12 月 13 日，包括本公司控股子公司/企业济南复健、宁波复瀛在内的 5 方投资人签订《济南基金合伙协议》，以共同出资设立济南基金。该基金募集资金 人民币 50,000 万元，主要投资以山东省为中心的生命科学及其上下游产业链处于初 创期、早中期的创新型企业。2024 年 3 月 12 日，该基金于中基协完成私募投资基 金备案。 有关该基金募集及过往投资人变动的详情，请见本公司 2023 年 12 月 14 日、2024 年 3 月 14 日、2024 年 10 月 11 日于《中国证券报》《上海证券报》《证券时报》 和上海证券交易所网站 ...

证券代码：600196 股票简称：复星医药 编号：临 2026-003 上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获受理的公告 根据 IQVIA CHPA 最新数据 1，2024 年，注射用乳糖酸红霉素于中国境内（不包 括港澳台地区）的销售额约为人民币 1.70 亿元。 三、对上市公司的影响及风险提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司苏州 二叶制药有限公司就注射用乳糖酸红霉素（以下简称"该药品"）的药品注册申请 于近期获国家药品监督管理局受理。 二、该药品的基本信息及研究情况 该药品为化学药品，拟用于（1）当口服给药不可行或感染的严重程度需要快速 达到高红霉素血清浓度时，用于治疗由特定微生物敏感株引起的感染，（2）预防风 湿热初发，（3）预防风湿热复发，（4）预防细菌性心内膜炎。 截至 2025 年 12 月，本集团（即本公司及控股子公司/单位，下同）现阶段针对 该药品的累计研发投入约为人民币 633 万元（未经审计）。 ...

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has recently had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration [1] Group 1: Company Developments - The cumulative R&D investment for the injectable lactulose erythromycin by the group is approximately RMB 6.33 million (unaudited) as of December 2025 [1] - The sales revenue for injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 according to IQVIA CHPA data [1]

证券代码：600196 股票简称：复星医药 编号：临 2026-004 上海复星医药（集团）股份有限公司 关于控股子公司激励计划实施进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 ●根据控股子公司复星安特金实际情况以及后续发展计划，本公司及复星安 特金董事会分别于 2026 年 1 月 14 日作出决议，批准对 2024 年 8 月 27 日已获采 纳之复星安特金首期激励计划进行修订，其中主要包括（1）该计划所涉激励工 具由期权变更为限制性股权、及（2）配套设置限制性股权解锁条件。 基于上述修订，同日，复星安特金董事会亦就截至当日存续有效的激励权益 份额作出确认。 ●本次修订已经本公司第十届董事会第二十次会议审议通过，根据上证所 《上市规则》，该事项无需提请股东会批准。 一、复星安特金首期激励计划及本次进展 （一）首期激励计划概述 为有效吸引、保留对复星安特金集团业务成长具有重要影响和贡献的核心团 队和关键人才，激发创业激情，助力企业长远发展，2024 年 8 月 27 日，本公司 及控股子公司 ...

Group 1 - Zhonghui Fuhong (Tianjin) Equity Investment Fund Partnership (Limited Partnership) has been established with a capital contribution of 547 million yuan, focusing on private equity investment, investment management, and asset management activities [1] - The partnership is co-funded by Zhonghui Life Insurance Co., Ltd., Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (a wholly-owned subsidiary of Fosun Pharma), and Hongyi Private Equity Fund Management (Tianjin) Partnership (Limited Partnership) [1] - The registered office is located in the Tianjin Free Trade Zone, specifically in the Central Business District [2]

合伙人信息显示，该基金由中汇人寿保险股份有限公司、上海复星医药产业发展有限公司、弘毅私募基金管理（天津）合伙企业（有限合伙）共同出资。 投时关键词：复星医药（600196.SH） | | 自公司 都在用的商业直向工具 | 查关系 普风险 普敦版 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 中汇复弘(天津)股权投资基金合伙企业(有限合伙) | 0 天蝎一下 部应用 ▼ 企业级产品。 | | 商务合作 | 由 开通会员 · | 鱼 费米· | | 基本信息 3 | 法律诉讼 | 经营风险 | 经营信息 公司发展 | | 知识产权 | 历史信息 ◎ | | | 工商信息 @ | | | | | | | で天眼直 | | 历史工商信息0 工商信息 | | | | | | | 대 특별 | | 企业名称 | 中汇复弘(天津)股权投资基金合伙企业(有限合伙) | | | | | | | | 执行事务合伙人 3 | 弘毅私募基金管理(天津)合伙 企业(有限合伙) (含新代表) Di 围逸清) 委派代表:曹永刚(宋源于中墓 | 登记状 ...

Core Viewpoint - The establishment of the Zhonghui Fuhong Equity Investment Fund in Tianjin marks a new experiment in the integration of finance and industry within the healthcare sector, aiming to unlock new investment paradigms through collaboration among insurance capital, industrial capital, and professional fund management [2][3][4] Group 1: Fund Establishment and Structure - The Zhonghui Fuhong Equity Investment Fund has a total capital of 547 million RMB and is a partnership involving Zhonghui Life Insurance, Fosun Pharma, and Hongyi Private Equity [2] - The fund's operational scope includes private equity investment, investment management, and asset management, indicating a focus on healthcare investments [2] Group 2: Strategic Implications for Participants - The collaboration between insurance capital, industrial capital, and general partners (GPs) is expected to reshape the underlying logic of healthcare investments, with insurance capital seeking stable returns and industrial capital aiming for asset-light transformation [2][3] - Fosun Pharma's strategy involves divesting non-core assets to recover cash flow, which will then be reinvested into high-margin sectors like innovative drugs and CXO services through the fund [3] Group 3: Regional Advantages and Policy Support - Tianjin's status as a free trade zone provides significant policy advantages, such as tax refunds for individual limited partners and facilitation of cross-border capital flows, which lower operational costs for the fund [3][4] - The biopharmaceutical industry park in Tianjin aligns well with Fosun Pharma's strategic layout, enhancing the region's attractiveness for capital investment [3] Group 4: Future Outlook and Potential Impact - The success of the Zhonghui Fuhong Fund could set a precedent for other insurance companies and may lead to a shift in the investment landscape, potentially breaking the dominance of Beijing and Shanghai in healthcare equity investments [3][4] - The efficiency of project exits and the outcomes of industrial collaboration over the next year will determine whether this initiative can evolve from a case study to a replicable model [4]

1月14日金融一线消息，天眼查显示，近日，中汇复弘（天津）股权投资基金合伙企业（有限合伙）成 立，出资额5.47亿元，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息 显示，该合伙企业由中汇人寿保险股份有限公司、复星医药全资子公司上海复星医药产业发展有限公 司、弘毅私募基金管理（天津）合伙企业（有限合伙）共同出资。 | 工商信息 ● | | | | | | 医 胶摇纠错 | 已天眼色 | | --- | --- | --- | --- | --- | --- | --- | --- | | 工商售應 历史工商信息( | | | | | | | 0 12 6 9 | | 企业名称 | 中汇直弘(天津)股权投资基金台伙企业(有限合伙) | | | | | | | | | 弘扬松基基金管理 (大量)合伙 到日状态(1) 企业(有限合伙) (面试代表: | 存状 | | | | | | | 执行覆务台伙人(3 | 3 厥逸涛) 的单点点 受期代表:疆水刚(火漏子中赞 | 天景评分 8 | | | | 96 | | | | 成立日期 801 | 2026-01-08 | | | | | | | 均 ...

Group 1 - The core point of the article is the establishment of Zhonghui Fuhong (Tianjin) Equity Investment Fund Partnership (Limited Partnership) with a capital contribution of 547 million yuan, focusing on private equity investment, investment management, and asset management activities [1] - The partnership is jointly funded by Zhonghui Life Insurance Co., Ltd., a wholly-owned subsidiary of Fosun Pharma (600196) Shanghai Fosun Pharma Industry Development Co., Ltd., and Hongyi Private Equity Fund Management (Tianjin) Partnership (Limited Partnership) [1] - The establishment of this fund indicates a strategic move in the private equity investment sector, highlighting the collaboration between insurance and pharmaceutical companies [1]